Sign in
Taking people in United StatesNo phase

How talk-based sleep treatment affects stress hormones in people with long-term insomnia

Studies how CBT-I changes cortisol in adults with chronic insomnia.

Key facts

Who runs it
University of Notre Dame
Where
Notre Dame, United StatesSee the site
Trial code
Registry title
Restorative Effects of Sleep on Everyday Health and Wellbeing: A Treatment Study
Status
Recruiting
People taking part
115 people, planned
Started
29 Sept 2025
Expected to end
31 Aug 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Cognitive Behavioral Therapy for Insomnia
Record updated
23 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic insomnia who speak English. Half will sleep less than 6 hours a night and half 6 or more hours.

Age
18 years or older
Sex
All sexes
Disease stage
Chronic insomnia that meets DSM-5 criteria for Insomnia Disorder, checked by a screener and a short clinical interview.
Earlier treatment
People currently taking sleep medication, medication for hormone (endocrine) problems, or medication that affects sleep or cortisol cannot join.

Main reasons for not taking part

  • Sleep disorders other than insomnia, or hormone (endocrine) disorders
  • Shift work or another extreme sleep schedule
  • Heavy alcohol or drug use, or serious mental illness
  • Chronic medical conditions that less sleep could make worse
  • Women who are pregnant, breastfeeding, or in the stage just before menopause

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • At least 18-years-old
  • Speaks English
  • Meets DSM-5 criteria for Insomnia Disorder, determined through initial screener than verified during brief clinical interview (at intake)

Who cannot take part

  • Currently taking sleep medication
  • Currently taking medication for endocrine dysfunction
  • Currently taking medication that interferes with sleep or cortisol levels
  • Sleep disorders other than Insomnia
  • Endocrine disorders
  • Serious mental illness
  • Chronic medical conditions (which may be exacerbated by sleep restriction)
  • Extreme sleep schedule (i.e. shift workers)
  • Excessive alcohol/substance use or AUD/SUD
  • Pregnant or nursing women
  • Women in the peri-menopausal stage due to irregular menses and fluctuations in sex hormones

Where in United States

  • University of Notre DameNotre Dame, United StatesContact: Ivan VargasTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the mechanisms through which Cognitive Behavioral Therapy for Insomnia (CBT-I) leads to improvements in sleep and sleep-related daytime outcomes, specifically as it relates to cortisol and the hypothalamic-pituitary-adrenal (HPA) axis, the body's primary stress response system. The primary research aims are: 1) To determine whether changes in cortisol functioning are related to improvements in sleep consolidation (4-week CBT-I), sleep duration (10-week CBT-I) or both, AND 2) to examine whether these improvements are more pronounced among individuals with insomnia and short sleep duration (compared to insomnia with 'normal' sleep duration).This study will recruit individuals with chronic insomnia: half with reported short sleep duration (less than 6 hours of sleep on an average night) and half with reported non-short sleep duration (6 or more hours per night). Participants will complete an in-lab assessment on four different occasions. During the first visit, they will confirm eligibility, complete an online survey, complete an in-lab stress task (with saliva samples), and provide a hair sample to measure cortisol (a hormone). They will then be sent home with a home sleep test as a final eligibility check (to rule out sleep disorders other than insomnia), an actigraphy watch to measure their sleep, and collection tubes to provide saliva samples to measure cortisol. We will then track the participants' sleep using online daily diaries and actigraphy for four week. Following the 4-week baseline period, participants will come in for a second in-lab visit (same procedures as the first visit) and then be randomized to receive either four or ten weeks of Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is a empirically supported behavioral treatment for insomnia and the first-line treatment for chronic insomnia. Sleep patterns and insomnia symptoms will continue to be monitored via diaries during the intervention phase. The third visit will take place once the participant has completed the intervention and the fourth visit will occur three months following the third visit (3 months post-treatment). The 3rd and 4th visits will again replicate the same procedures conducted during the initial lab visit.

The 2 groups in the trial

  • 4-Week CBT-ITreatment being tested

    Participants in this arm will receive 4 weeks of CBT-I.

    Treatment: Cognitive Behavioral Therapy for Insomnia

  • 10-Week CBT-ITreatment being tested

    Participants in this arm will receive 10 weeks of CBT-I.

    Treatment: Cognitive Behavioral Therapy for Insomnia

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of CBT-I on Hypothalamic-Pituitary-Adrenal (HPA)-Axis Functioning in Participants With Chronic Insomnia
Plain-language title
How talk-based sleep treatment affects stress hormones in people with long-term insomniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
23 April 2026